⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CAMP News
CAMP4 Therapeutics Corporation Common Stock
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
globenewswire.com
CAMP
SPM COMMUNICATIONS UNVEILS NEW BRAND AND WEBSITE
prnewswire.com
CC
UTZ
EAT
PZZA
TACO
CAMP
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
globenewswire.com
CAMP
Form 8-K
sec.gov
CAMP
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
globenewswire.com
CAMP
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
globenewswire.com
CAMP
CAMP4 to Participate in Upcoming Investor Conferences
globenewswire.com
CAMP
Form 8-K
sec.gov
CAMP
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com
CAMP
Form 8-K
sec.gov
CAMP